Copyright
©The Author(s) 2023.
World J Gastrointest Endosc. Mar 16, 2023; 15(3): 177-190
Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.177
Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.177
Table 4 Pooled adverse event data among included endoscopic radiofrequency ablation studies
| Adverse event | ERFA-stent n (%) | Stent alonen (%) | P value |
| Biliary stent occlusion | 34 (81.0) | 31 (67.3) | 0.148 |
| Cholangitis | 27 (25.5) | 15 (19.0) | 0.298 |
| Cholecystitis | 8 (12.5) | 0 (0) | 0.010 |
| Pancreatitis | 4 (4.2) | 3 (4.7) | 0.875 |
| Hemobilia/Bleeding | 1 (1.5) | 1 (1.5) | 1.000 |
- Citation: Rebhun J, Shin CM, Siddiqui UD, Villa E. Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review. World J Gastrointest Endosc 2023; 15(3): 177-190
- URL: https://www.wjgnet.com/1948-5190/full/v15/i3/177.htm
- DOI: https://dx.doi.org/10.4253/wjge.v15.i3.177